Newswise — Malmö, Sweden and NEW YORK – QPharma and Biorings have entered into a definitive agreement for product development and GMP manufacture of a non-hormonal intra-vaginal ring for contraception – a novel approach to contraception. The investigational drug product is a multipurpose preventation technology (MPT) for women’s reproductive and sexual health.
The benefits of this new and effective prevention technology are No-hormone related side effects, No- systemic side effects, as well as improved compliance and convenience (self-administered and 28-day delivery).
The technology makes use of two active ingredients: Ferrous gluconate, which affects the lipid bilayer of the sperm tail leading to spermiostasis, and Ascorbic acid which acts as a reducing agent resulting in increased viscosity of the cervical mucus that works as a barrier to inhibit sperm penetration.
“The selection of QPharma to support the development and GMP manufacture of this non-hormonal contraceptive is very interesting for us. We look forward to working with BioRings to bring this valuable new class of product into the market,” said Mr. Kenneth Stokholm, Managing Director of QPharma. “Our competence in polymer systems and drug release at QPharma will help us meet the development requirements of this multipurpose prevention technology (MPT).”
Said Sidney Lerner, President of BioRings LLC, “We originated this project with a research team consisting of my co-inventors Drs Brij Saxena and Mukul Singh at Weill-Cornell. We were inspired to learn from a national survey of 1,000 women contraceptive-users that 62% stated they would switch to a safer, non-hormonal intra-vaginal ring product if it were proven equally effective. BioRings is now on its path through the regulatory process, and we look forward to making this safer, non-hormonal option available globally by the end of the decade.”
About QPharmaQPharma is a contract developer and manufacturer of pharmaceuticals, based in Sweden. For more than 35 years, our manufacturing plant and development labs have successfully met national, EU and FDA inspections. Clients are ranging from top-10 pharmaceutical companies to small innovative start-ups.